

Population pharmacokinetics of imipenem bone concentrations in pigs



Anne-Laure Flaugère¹, Michel Carles², Edith Ramain², Audrey Boulamery¹, Nicolas Simon¹.

¹Laboratoire de pharmacologie médicale et clinique APHM, Université de la Méditerranée, Marseille, France; ²Département d'Anesthésie-Réanimation, Hôpital de l'Archet II, Nice, France.


INTRODUCTION

+ Imipenem (IPM) is a broad-spectrum β-lactam antibiotic frequently used in intensive care units to treat nosocomial infections and BGN infections.

+ It allows to treat severe infections of all body systems notably bone infections.

+ Interestingly, IPM is a good drug candidate for microdialysis studies (fig 1).

The objective of the present study was to investigate the bone distribution of IPM by microdialysis in healthy pigs in order to extrapolate to human.



• 8 healthy pigs (26-30kg) were included.

An arterial catheter and a medullar bone microdialysis (figure1) probe were inserted in the left posterior tibia after a general anesthesia.

METHOD

Pigs received an intravenous infusion of 15mg/kg of IPM over a 30 min period.

Blood samples and bone dialysates were collected at 5, 15, 30, 45, 60, 120, 180, 240 and 300 min following infusion.

IPM concentrations in plasma and microdialysat were determined by a validated HPLC method with UV-VIS detection (Dionex detector UVD170U).

The in vivo recovery of the microdialysis was evaluated by retrodialysis (63%).

• Data were analysed using the non linear mixed effect modeling software program NONMEM (version VI.2).

Plasma and bone concentrations were described using the nonmem subroutines ADVAN3 and ADVAN11.

V2

V1

V3

Figure4:

K12

K13

K21

K31

CL

Observed

concentrations of IPM (DV) versus

predicted concentrations (PRED).

bone

Figure 1 : Microdialysis concept

RESULTS

A 3-compartments model best described the whole dataset (table 1 figure 2). Bone and plasma concentrations are represented on figure 3 and 4.

The model of pharmacokinetic in pig was validated using a bootstrap analysis and goodness of fit plots with normalized predictive distribution error.

Human bone concentrations were simulated using the pig constant rates between plasma and bone, together with a published model in HV. 3 doses imipenem were tested : 250mg, 500mg and 750mg (figure 5).

Table 1 : Final estimates for population PK parameters of imipenem in pigs.

| | Value | se (%) | IC 95 Lower - higher | |
|-----------------------------|-------|-----------|-------------------------|-------|
| | | | | |
| PK parameters | | | | |
| CL (L/h) | 7.08 | 13.3 | 5.57 | 10.62 |
| V1 (L) | 2.56 | 7.70 | 2.20 | 3.07 |
| Q (L/h) | 3.43 | 18.0 | 2.59 | 5.44 |
| V2 (L) | 2.59 | 9.90 | 2.18 | 3.21 |
| K13 (1/h) | 0.21 | 45.0 | 0.11 | 0.43 |
| K31(1/h) | 2.46 | 23.0 | 1.63 | 3.27 |
| InterIndividual Variability | | | | |
| ω CL (%) | 22 | 44 | 10.20 | 44.30 |
| ω K13 (%) | 61 | 25 | 4.86 | 69.60 |
| Residual variability | | | | |
| ε prop Plasma (%) | 22 | 33 | 14.00 | 29.30 |
| ε prop Bone (%) | 37 | 43 | 16.20 | 41.90 |

Table2 : NONMEM plasma results in healthy pigs compared CL = total clearance to healthy human parameters.

| PK | Digo (20kg) | Healthy Volunteers [1] | |
|-------------|-------------|---------------------------|--|
| parameters | Pigs (30kg) | | |
| CL (L/h/kg) | 0.25 | 0.17+/-0.02 | |
| V1 (L/kg) | 0.085 | 0.16+/-0.04 | |
| V2 (L/kg) | 0.086 | 0.07 | |
| Vss (L/kg) | 0.17 | 0.23+/-0.03 | |
| k12 (1/h) | 1.34 | 0.98+/-0.20 | |
| k21 (1/h) | 1.32 | 1.73+/-1.11 | |

Figure3: Observed plasma concentrations of IPM (DV) versus predicted concentrations (PRED).




Figure 2 : The PK model.





Figure 5 : Simulated bone concentrations of IPM in human based on a pig model with 3 differents doses.



Vss = volume of distribution at steady state CONCLUSION

The estimation of total clearance (0.25 L/h/kg) and volume of distribution (0.17 L/kg) in pigs are in agreement with those obtained in human (0.17 L/h/kg and 0.23 L/kg). These parameters are of interest because imipenem is a time-dependent antibiotic (Time above MIC > 4mg/L).

• Our model can be used to predict plasma to bone transfert of IMP in human with the hypothesis that the process are similar between the 2 species.

V1 =central volume of distribution

Q =intercompartmental clearance

peripheral to central compartment

V3 = bone volume of distribution

to peripheral compartment

to bone compartment

the central compartment

V2= peripheral volume of distribution

K12 = first order intercompartment rate constant from centra

K21 = first order intercompartment rate constant from

* The simulations show that bone concentrations decrease below the MIC within the 8h requiring 3-4 administrations per day.

Our pig model with microdialysis is a useful tool for evaluation of the bone concentrations and allows extrapolation to human.

Reference:

[1] Standiford, H.C., et al., Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother, 1986. 29(3): p. 412-7.